Compare TNXP & GGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | GGR |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | Taiwan |
| Employees | 142 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 83.3M |
| IPO Year | 2008 | 2021 |
| Metric | TNXP | GGR |
|---|---|---|
| Price | $5.14 | $2.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $44.50 | N/A |
| AVG Volume (30 Days) | ★ 929.5K | 12.6K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $319.65 | $4.97 |
| Revenue Next Year | $101.60 | $6.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $5.05 | $2.02 |
| 52 Week High | $20.58 | $5.43 |
| Indicator | TNXP | GGR |
|---|---|---|
| Relative Strength Index (RSI) | 13.33 | 44.31 |
| Support Level | N/A | $2.80 |
| Resistance Level | $12.99 | $3.32 |
| Average True Range (ATR) | 0.51 | 0.18 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 3.92 | 9.43 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.